Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.6K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

3.2K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.2K
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

44
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
44
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

1.7K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.7K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Successful treatment of congenital myasthenic syndrome caused by a novel compound heterozygous variant in RAPSN.

Brain & development·2021
Same author

Visualizing Muscle Sialic Acid Expression in the GNED207VTgGne-/- Cmah-/- Model of GNE Myopathy: A Comparison of Dietary and Gene Therapy Approaches.

Journal of neuromuscular diseases·2021
Same author

FKRP mutations cause congenital muscular dystrophy 1C and limb-girdle muscular dystrophy 2I in Asian patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2021
Same author

A recurrent homozygous ACTN2 variant associated with core myopathy.

Acta neuropathologica·2021
Same author

Neuropathy/intranuclear inclusion bodies in oculopharyngodistal myopathy: A case report.

eNeurologicalSci·2021
Same author

Myoclonic Epilepsy with Ragged-red Fibers with Intranuclear Inclusions.

Internal medicine (Tokyo, Japan)·2021

Related Experiment Video

Updated: Apr 27, 2026

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

22.7K

GNE myopathy: current update and future therapy.

Ichizo Nishino1, Nuria Carrillo-Carrasco2, Zohar Argov3

  • 1Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan.

Journal of Neurology, Neurosurgery, and Psychiatry
|July 9, 2014
PubMed
Summary

GNE myopathy, a genetic muscle disorder, presents with progressive weakness. Early diagnosis is crucial as treatments targeting sialic acid pathways are emerging.

Keywords:
MUSCLE DISEASEMYOPATHYNEUROMUSCULAR

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.1K

Related Experiment Videos

Last Updated: Apr 27, 2026

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration
06:35

In Vivo Electrophysiological Measurement of Compound Muscle Action Potential from the Forelimbs in Mouse Models of Motor Neuron Degeneration

Published on: June 15, 2018

22.7K
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

9.0K
Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction
11:07

Engineering and Characterization of an Optogenetic Model of the Human Neuromuscular Junction

Published on: April 14, 2022

2.1K

Area of Science:

  • Genetics and Molecular Biology
  • Neuromuscular Disorders
  • Biochemistry

Background:

  • GNE myopathy is an inherited muscle-wasting condition caused by mutations in the GNE gene.
  • This gene is vital for producing sialic acid, a component of cell surfaces.
  • The disease typically manifests as progressive muscle weakness, particularly in the distal extremities.

Purpose of the Study:

  • To highlight the key diagnostic features of GNE myopathy.
  • To emphasize the importance of accurate and timely diagnosis for therapeutic intervention.
  • To introduce updated mutation nomenclature for the GNE gene.

Main Methods:

  • Review of clinical presentation, including typical onset and progression of muscle weakness.
  • Analysis of characteristic histopathological findings in muscle biopsies, such as rimmed vacuoles.
  • Genetic confirmation through GNE gene sequencing.

Main Results:

  • GNE myopathy is characterized by distal muscle weakness (e.g., foot drop) in early adulthood, progressing to involve other limbs while sparing quadriceps.
  • Muscle biopsies show distinctive 'rimmed' vacuoles, protein aggregates, and fiber size variation.
  • Genetic testing confirms the diagnosis via GNE gene mutations.

Conclusions:

  • Accurate diagnosis of GNE myopathy is essential given ongoing therapeutic developments.
  • Understanding the genetic basis and clinical manifestations aids in early identification.
  • Emerging treatments focus on the sialic acid pathway, underscoring the need for prompt diagnosis.